In the nilotinib-treated CP-CML (PT) cases, the normal levels of CD5L were, however, restored [(2.77 ± 1.37 ng/ml), Fig. 3B]. Here, CD5L is linked to chronic myelogenous leukemia, BCR-ABL1 positive.